Additionally, the administration of recombinant sclerostin inhibited, through LRP6, the activity of TNF-α-induced (but not IL-1-induced) MAP: p38 and ERK kinases, and as a result, the activity of NFκB in synoviocytes from mice and in those obtained from RA patients as well. Here, TNF is linked to rheumatoid arthritis.